↓ Skip to main content

Dove Medical Press

The clinical characteristics and prognostic analysis of Chinese advanced NSCLC patients based on circulating tumor DNA sequencing

Overview of attention for article published in OncoTargets and therapy, January 2018
Altmetric Badge

About this Attention Score

  • Above-average Attention Score compared to outputs of the same age and source (53rd percentile)

Mentioned by

twitter
2 X users
reddit
1 Redditor

Citations

dimensions_citation
5 Dimensions

Readers on

mendeley
11 Mendeley
Title
The clinical characteristics and prognostic analysis of Chinese advanced NSCLC patients based on circulating tumor DNA sequencing
Published in
OncoTargets and therapy, January 2018
DOI 10.2147/ott.s154589
Pubmed ID
Authors

Chuangzhou Rao, Liangqin Nie, Xiaobo Miao, Yunbao Xu, Bing Li, Tengfei Zhang

Abstract

Circulating tumor DNA (ctDNA) is a noninvasive and real-time marker for tumor diagnosis, prognosis, and prediction. However, further investigations about ctDNA prognostic and predictive value are still needed, and conclusions from several studies were inconsistent. We performed capture-based targeted ultradeep sequencing on liquid biopsies from a cohort of 34 advanced Chinese non-small-cell lung cancer (NSCLC) patients and analyzed the clinical use of ctDNA in this study. On the basis of clinical characteristics of the 34 NSCLC patients, we found that brain metastasis correlated with shorter progression-free survival (PFS) and is more prone to happen in younger patients. After ctDNA sequencing, we analyzed the prognostic value of baseline ctDNA. In osimertinib-treated group, high max allelic fraction (maxAF) correlated with shorter PFS. But for the cohort of 34 patients, no correlation can be observed between maxAF and PFS. We also presented two cases to demonstrate the value of disease progression prediction by ctDNA, which can be detected earlier than clinical response. In this study, we demonstrated that ctDNA is a prognostic marker for evaluating treatment response and predicting recurrence in advanced NSCLC. Further investigations with larger cohort and uniformed patient background are still needed to validate our findings.

X Demographics

X Demographics

The data shown below were collected from the profiles of 2 X users who shared this research output. Click here to find out more about how the information was compiled.
Mendeley readers

Mendeley readers

The data shown below were compiled from readership statistics for 11 Mendeley readers of this research output. Click here to see the associated Mendeley record.

Geographical breakdown

Country Count As %
Unknown 11 100%

Demographic breakdown

Readers by professional status Count As %
Researcher 3 27%
Student > Ph. D. Student 2 18%
Other 1 9%
Student > Master 1 9%
Student > Postgraduate 1 9%
Other 0 0%
Unknown 3 27%
Readers by discipline Count As %
Biochemistry, Genetics and Molecular Biology 3 27%
Agricultural and Biological Sciences 2 18%
Pharmacology, Toxicology and Pharmaceutical Science 1 9%
Psychology 1 9%
Medicine and Dentistry 1 9%
Other 0 0%
Unknown 3 27%
Attention Score in Context

Attention Score in Context

This research output has an Altmetric Attention Score of 1. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 05 February 2018.
All research outputs
#17,292,294
of 25,382,440 outputs
Outputs from OncoTargets and therapy
#1,147
of 3,016 outputs
Outputs of similar age
#283,799
of 449,550 outputs
Outputs of similar age from OncoTargets and therapy
#25
of 69 outputs
Altmetric has tracked 25,382,440 research outputs across all sources so far. This one is in the 21st percentile – i.e., 21% of other outputs scored the same or lower than it.
So far Altmetric has tracked 3,016 research outputs from this source. They receive a mean Attention Score of 2.9. This one has gotten more attention than average, scoring higher than 52% of its peers.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 449,550 tracked outputs that were published within six weeks on either side of this one in any source. This one is in the 27th percentile – i.e., 27% of its contemporaries scored the same or lower than it.
We're also able to compare this research output to 69 others from the same source and published within six weeks on either side of this one. This one has gotten more attention than average, scoring higher than 53% of its contemporaries.